Painful diabetic peripheral neuropathy in a managed care setting: Patient identification, prevalence estimates, and pharmacy utilization patterns

Population Health Management

Volumn 11, Issue 6, 2008, Pages 317-328

  Hartsfield, Cynthia L ^a,b   Korner, Eli J ^a,b   Ellis, Jennifer L ^a   Raebel, Marsha A ^a,b   Merenich, John ^a   Brandenburg, Nancy ^c  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; DIABETIC NEUROPATHY; DRUG UTILIZATION; HUMAN; MANAGED CARE; NEUROPATHIC PAIN; PATIENT COMPLIANCE; PREVALENCE; QUALITY OF LIFE;

AGED; ALGORITHMS; CLINICAL AUDIT; COLORADO; DATABASES AS TOPIC; DIABETIC NEUROPATHIES; DRUG UTILIZATION; HUMANS; INSURANCE CLAIM REVIEW; INTERNATIONAL CLASSIFICATION OF DISEASES; MANAGED CARE PROGRAMS; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT IDENTIFICATION SYSTEMS; PREDICTIVE VALUE OF TESTS; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 58149231233     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2008.0015     Document Type: Article

References (53)

1. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-824.
2. Martyn CN, Hughes RAC. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997;62:310-318.
3. Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Rev. 1999;7:245-252.
4. Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population ≥ 40 years of age with and without diabetes: 1999-2000 National Health and Nutrition Examination Survey. Diabetes Care. 2004;27:1591-1597.
5. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976-982.
6. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518-1522.
7. Boulton AJM. Management of diabetic peripheral neuropathy. Clin Diabetes. 2005;23:9-15.
8. Tamer A, Yildiz S, Yildiz N, et al. The prevalence of neuropathy and relationship with risk factors in diabetic patients: a single-center experience. Med Princ Pract. 2006;15: 190-194.
9. Valensi P, Giroux C, Seeboth-Ghalavini B, Attali JR. Diabetic peripheral neuropathy: effects of age, duration of diabetes, glycemic control, and vascular factors. J Diabetes Complications. 1997;11:27-34.
10. Booya F, Bandarian F, Larijani B, Pajouhi M, Nooraei M, Lotfi J. Potential risk factors for diabetic neuropathy: a case control study. BMC Neurol. 2005;5:24.
11. Daousi C, Benbow SJ, Woodward A, Macfarlane IA. The natural history of chronic painful peripheral neuropathy in a community diabetes population. Diabet Med. 2006;23: 1021-1024.
12. Boulton AJM, Knight G, Drury J, Ward JD. The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population. Diabetes Care. 1985;8:125-128.
13. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:89-94.
14. Jensen T, Backonja MM, Hernandez Jimenez S, Tesfaye S, Valensi P, Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain. Diabetes Vasc Dis Res. 2006;3:108-119.
15. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997;48:332-338.
16. Gore M, Brandenburg N, Dukes E, Hoffman D, Tai K-S, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374-385.
17. Quattrini C, Tesfaye S. Understanding the impact of painful diabetic neuropathy. Diabetes Metab Res Rev. 2003;19(suppl 1):S2-S8.
18. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: Clinical and quality-of-life issues. Mayo Clin Proc. 2006;4 (suppl):S3-S11.
19. Chong MS, Bajwa ZH. Diagnosis and treatment of neuropathic pain. J Pain Symptom Manag. 2003;25(5 suppl): S4-S11.
20. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92:147-157.
21. Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain. 2003;19:306-314.
22. Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006;108: 477-481.
23. Zelman DC, Gore M, Dukes E, Tai K-S, Brandenburg N. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage. 2005;29:401-410.
24. Herr K. Neuropathic pain: a guide to comprehensive assessment. Pain Manag Nurs. 2004;5:9-18.
25. Jensen MP, Friedman M, Bonzo D, Richards P. The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clin J Pain. 2006;22:97-103.
26. Barbano R, Hart-Gouleau S, Pennella-Vaughan J, Dworkin RH. Pharmacotherapy of painful diabetic neuropathy. Curr Pain Headache Re. 2003;7:169-177.
27. Backonja M, Galer BS. Pain assessment and evaluation of patients who have neuropathic pain. Neurol Clin. 1998;16: 776-789.
28. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm. 2004;61:160-173.
29. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27:1458-1486.
30. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2005;64:199-207.
31. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care. 1990;13:513-521.
32. Dworkin RH, Gitlin MJ. Clinical aspects of depression in chronic pain patients. Clin J Pain. 1991;7:79-94.
33. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350-354.
34. Ziegler D. Polyneuropathy in the diabetic patient-update on pathogenesis and management. Nephrol Dial Transplant. 2004;19:2170-2175.
35. Simmons Z, Feldman EL. Update on diabetic neuropathy. Curr Opin Neurol. 2002;15:595-603.
36. International Diabetes Federation. Diabetes prevalence. Available at: 〈http://www.idf.org/home/index.cfm?node= 264〉. Last accessed September 25, 2008.
37. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
38. Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic neuropathies. A statement by the American Diabetes Association. Diabetes Care. 2005;28:956-962.
39. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Mayo Clinic Proc. 2006;81(4 suppl):S12-S25.
40. Mendell JR, Sahenk Z. Painful sensory neuropathy. N Engl J Med. 2003;348:1243-1255.
41. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain. Diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524-1534.
42. Gordon DB, Love G. Pharmacologic management of neuropathic pain. Pain Manag Nurs. 2004;5:19-33.
43. Poncelet AN. An algorithm for the evaluation of peripheral neuropathy. Am Fam Phys. 1998;57:755-764.
44. Brenner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461.
45. Wei L, Wang J, Thompson P, Wong S, Struthers AD, Mac-Donald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart. 2002;88:229-233.
46. Kopjar B, Sales AE, Pineros SL, Sun H, Li Y, Hedeen AN. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol. 2003;92:1106-1108.
47. Abraha I, Montedori A, Stracci F, Rossi M, Romagnoli C. Statin compliance in the Umbrian population. Eur J Clin Pharmacol. 2003;59:659-661.
48. Ehde DM, Czerniecki JM, Smith DG, et al. Chronic phantom sensations, phantom pain, residual limb pain, and other regional pain after lower limb amputation. Arch Phys Med Rehabil. 2000;81:1039-1044.
49. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143-149.
50. Boulton AJ, Armstrong WD, Scarpello JH, Ward JD. The natural history of painful diabetic neuropathy: a 4-year study. Postgrad Med J. 1983;59:556-559.
51. Pfeifer MA, Ross DR, Schrage JP, et al. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care. 1993;16:1103-1115.
52. Benbow SJ, Chan AW, Bowsher D, Macfarlane IA, Williams G. A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabet Med. 1994;11:17-21.
53. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 1988;33:11-23.